Docetaxel hydrate
Based on 183 publication(s) in Google Scholar
Docetaxel hydrate (RP-56976 hydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel hydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel hydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel hydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel hydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel hydrate can be used in cancer-related research.
For research use only. We do not sell to patients.
- CAS No.: 700367-34-6
- Formula: C43H55NO15
- Molecular Weight:825.89
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Docetaxel hydrate
More- Signal Transduct Target Ther. 2026 Jun 17;11(1):238. [Abstract]
- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2022 Sep 12;7(1):317. [Abstract]
- J Hematol Oncol. 2023 May 3;16(1):46. [Abstract]
- J Clin Oncol. 2026 Mar 2.
- Mol Cancer. 2026 May 13.
- Mol Cancer. 2024 May 9;23(1):83. [Abstract]
- Cancer Discov. 2026 Jun 22. [Abstract]
- Adv Mater. 2025 Jul 4:e2505231. [Abstract]
- Eur Urol. 2021 Jun;79(6):722-733. [Abstract]
- Cancer Res. 2025 Oct 9. [Abstract]
- Adv Funct Mater. 2023 Dec 15.
- ACS Nano. 2021 Apr 27;15(4):7179-7194. [Abstract]
- Redox Biol. 2026 Sep 2:97:104376.
- Sci Transl Med. 2024 Apr 3;16(741):eadj5705. [Abstract]
- Biomark Res. 2022 Jul 13;10(1):48. [Abstract]
- Acta Pharm Sin B. 2021 Apr;11(4):1069-1082. [Abstract]
- J Clin Invest. 2026 Mar 17:e200260. [Abstract]
- J Exp Clin Cancer Res. 2023 Aug 18;42(1):209. [Abstract]
- Adv Sci (Weinh). 2026 Mar;13(13):e11408. [Abstract]
- Adv Sci (Weinh). 2025 Jan;12(2):e2407662. [Abstract]
- Cell Rep Med. 2026 May 19;7(5):102757. [Abstract]
- Cell Rep Med. 2026 Feb 17;7(2):102622. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- Biomaterials. 2022 Oct:289:121783. [Abstract]
- J Transl Int Med. 2026 Mar 26;14(2):237-258. [Abstract]
- J Control Release. 2024 Dec:376:829-841. [Abstract]
- J Control Release. 2023 Jan:353:490-506. [Abstract]
- J Control Release. 2021 Jan 10:329:847-857. [Abstract]
- Cell Death Dis. 2026 Apr 3;17(1):449. [Abstract]
- Cell Death Dis. 2026 Mar 24;17(1):363. [Abstract]
- Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
- Cell Death Dis. 2024 Aug 7;15(8):571. [Abstract]
- Pharmacol Res. 2024 Jun:204:107208. [Abstract]
- Cancer Lett. 2025 Feb 1:610:217339. [Abstract]
- Cancer Lett. 2023 Sep 1:571:216338. [Abstract]
- J Immunother Cancer. 2021 Jul;9(7):e001758. [Abstract]
- Phytomedicine. 2024 Dec:135:156155. [Abstract]
- Phytomedicine. 2023 Aug:117:154921. [Abstract]
- Phytomedicine. 2023 Jan:109:154584. [Abstract]
- Phytomedicine. 2022 May:99:153939. [Abstract]
- Mater Today Bio. 2026 Mar 31:38:103086. [Abstract]
- ACS Sens. 2023 Feb 24;8(2):543-554. [Abstract]
- Genome Med. 2024 Jan 12;16(1):11. [Abstract]
- Cell Death Discov. 2026 Jul 8.
- J Transl Med. 2026 Jul 11.
- J Colloid Interface Sci. 2022 May 2;622:789-803. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2218522120. [Abstract]
- Diabetes. 2023 Jan 1;72(1):97-111. [Abstract]
- Oncogene. 2026 Jan;45(2):278-294. [Abstract]
- Oncogene. 2025 Nov;44(45):4405-4412. [Abstract]
- Int J Mol Med. 2024 Jul;54(1):60. [Abstract]
- Arch Pharm Res. 2024 Nov;47(10-11):829-853. [Abstract]
- Biofabrication. 2023 Jun 9;15(3). [Abstract]
- Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696. [Abstract]
- Free Radic Biol Med. 2026 Aug 16:252:493-508. [Abstract]
- Clin Transl Med. 2026 Jul;16(7):e70737.
- Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
- ACS Appl Mater Interfaces. 2024 Sep 25;16(38):50147-50159. [Abstract]
- ACS Appl Mater Interfaces. 2023 May 3;15(17):20697-20711. [Abstract]
- Cell Rep. 2024 Jul 3;43(7):114431. [Abstract]
- Br J Pharmacol. 2024 Nov;181(21):4279-4293. [Abstract]
- Cancer Cell Int. 2024 Dec 27;24(1):433. [Abstract]
- Cancer Cell Int. 2024 Jul 17;24(1):249. [Abstract]
- Drug Deliv Transl Res. 2021 Oct;11(5):2030-2051. [Abstract]
- J Agric Food Chem. 2024 Jul 31;72(30):16801-16811. [Abstract]
- Eur J Med Chem. 2018 Feb 25:146:157-170. [Abstract]
- Cell Biosci. 2023 Nov 25;13(1):215. [Abstract]
- Biochem Pharmacol. 2020 May;175:113865. [Abstract]
- Life Sci. 2026 Mar 15:389:124236. [Abstract]
- Life Sci. 2025 Jul 1:372:123646. [Abstract]
- Life Sci. 2021 Jan 1:264:118674. [Abstract]
- Life Sci. 2020 Sep 1:256:117983. [Abstract]
- Breast Cancer Res. 2024 Mar 19;26(1):48. [Abstract]
- Oncogenesis. 2026 Sep 28.
- Oncogenesis. 2026 Aug 20.
- Int J Pharm. 2023 Apr 5:636:122846. [Abstract]
- Commun Biol. 2026 Apr 2;9(1):718. [Abstract]
- Cancer Immunol Immunother. 2025 Nov 18;74(12):377. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Cancer Biol Ther. 2026 Dec 31;27(1):2676474. [Abstract]
- Clin Epigenetics. 2025 May 6;17(1):77. [Abstract]
- Pharmaceuticals (Basel). 2024 Apr 29;17(5):569. [Abstract]
- Int J Mol Sci. 2022 Nov 19;23(22):14385. [Abstract]
- Int J Mol Sci. 2018 Dec 21;20(1):28. [Abstract]
- Biol Direct. 2024 Sep 11;19(1):79. [Abstract]
- J Enzyme Inhib Med Chem. 2026 Dec;41(1):2622725. [Abstract]
- Microchem J. 2025 Oct 15;218:115702.
- ACS Omega. 2024 Feb 28;9(10):11870-11882. [Abstract]
- Chem Biol Interact. 2023 Mar 1:373:110372. [Abstract]
- J Mol Med (Berl). 2026 Mar 19;104(1):53. [Abstract]
- Mol Med Rep. 2020 Jul;22(1):67-76. [Abstract]
- Sci Rep. 2026 Aug 29.
- Sci Rep. 2025 Jul 4;15(1):23847. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Sci Rep. 2024 Mar 27;14(1):7303. [Abstract]
- Cancer Sci. 2024 Feb;115(2):412-426. [Abstract]
- Transl Oncol. 2023 Sep:35:101723. [Abstract]
- Sci Rep. 2023 Jun 3;13(1):9043. [Abstract]
- Eur J Med Res. 2025 Aug 4;30(1):704. [Abstract]
- Cancers (Basel). 2020 Jul 28;12(8):2092. [Abstract]
- J Cell Mol Med. 2025 Dec;29(23):e70972. [Abstract]
- J Pharm Investig. 2025 Sep 19.
- J Cell Mol Med. 2022 Apr;26(8):2392-2403. [Abstract]
- J Liposome Res. 2020 Jun;30(2):182-196. [Abstract]
- Mol Oncol. 2026 Jun 5. [Abstract]
- iScience. 2025 Oct 30;28(12):113908. [Abstract]
- iScience. 2025 Sep 9;28(10):113520. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2025 Jul 31;1872(8):120029. [Abstract]
- FEBS J. 2024 Jul;291(14):3249-3266. [Abstract]
- Pharm Res. 2025 Nov 18. [Abstract]
- BJU Int. 2025 Nov 3. [Abstract]
- BMC Cancer. 2025 Jul 1;25(1):1042. [Abstract]
- Front Biosci (Landmark Ed). 2025 Feb 20;30(2):25522. [Abstract]
- J Biol Chem. 2021 Jan-Jun:296:100276. [Abstract]
- PLoS Genet. 2025 Mar 31;21(3):e1011652. [Abstract]
- Int J Med Sci. 2026 Jan 1;23(1):161-176. [Abstract]
- Pathol Res Pract. 2025 Sep:273:156138. [Abstract]
- Breast Cancer. 2024 Dec 20:16:993-1004. [Abstract]
- Materials. 2020 Mar 2;13(5):1099. [Abstract]
- Micromachines. 2026 Mar 9;17(3):332. [Abstract]
- Mol Carcinog. 2025 Jan;64(1):192-208. [Abstract]
- Arch Biochem Biophys. 2023 Mar 15:737:109551. [Abstract]
- Reprod Toxicol. 2026 Jan:139:109110. [Abstract]
- Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. [Abstract]
- Front Oncol. 2019 Dec 19:9:1398. [Abstract]
- Chem Biol Drug Des. 2025 Feb;105(2):e70053. [Abstract]
- Biochem Biophys Rep. 2024 Jan 14:37:101639. [Abstract]
- Breast Cancer Res Treat. 2023 Jul;200(2):193-201. [Abstract]
- J Cancer Res Clin Oncol. 2022 Dec;148(12):3511-3520. [Abstract]
- J Therm Biol. 2026 Sep 28:141:104576.
- J Appl Polym Sci. 18 February 2022.
- J Microencapsul. 2020 Dec;37(8):543-556. [Abstract]
- J Microencapsul. 2019 Sep;36(6):552-565. [Abstract]
- Pharm Dev Technol. 2021 Oct;26(8):910-921. [Abstract]
- Int J Immunopathol Pharmacol. 2026 Jan-Dec:40:3946320261474427.
- PLoS One. 2026 Jan 21;21(1):e0341445. [Abstract]
- Discov Oncol. 2023 May 27;14(1):82. [Abstract]
- Clin Transl Oncol. 2022 Nov;24(11):2231-2240. [Abstract]
- Biochem Biophys Res Commun. 2026 Sep 24:832:154364.
- Biochem Biophys Res Commun. 2026 Jun 18:818:153767. [Abstract]
- Oncol Lett. 2022 Mar;23(3):101. [Abstract]
- Anticancer Drugs. 2022 Oct 1;33(9):871-882. [Abstract]
- Eur J Histochem. 2022 Oct 25;66(4). [Abstract]
- Biomed Chromatogr. 2022 Sep;36(9):e5417. [Abstract]
- Mol Biol Res Commun. 2022 Mar;11(1):11-20. [Abstract]
- Int J Clin Exp Pathol. 2017;10(3):3033-3042.
- Adv Urol. 2026 Apr 15;2026(1):7448726.
- Biomed Pharmacother. 2026 Sep:202:119803.
- Preprints.2026 Mar 3.
- bioRxiv. 2026 Mar 27.
- bioRxiv. 2026 Mar 18.
- bioRxiv. 2026 Feb 4:2026.02.02.701385. [Abstract]
- SSRN. 2025 Dec 26.
- Res Sq. 2025 Sep 7.
- bioRxiv. 2025 Sep 21.
- University of Granada. 2025.
- SSRN. 2025 Jun 4.
- bioRxiv. 2025 June 01.
- Res Sq. 2025 May 16:rs.3.rs-6590535. [Abstract]
- University of Granada. 2025.
- University of Beirut. 2025.
- bioRxiv. 2025 Jan 24:2025.01.22.632572. [Abstract]
- University of Minnesota. 2024.
- SSRN. 2024 Mar 22.
- bioRxiv. 2023 Nov 1:2023.10.29.564598. [Abstract]
- Biomed Pharmacother. 2023 Sep:165:115023. [Abstract]
- Preprints. 2023 Jul 13.
- Biomed Pharmacother. 2023 Jul:163:114751. [Abstract]
- University of Adelaide. 2023 Jan.
- Patent. US20230145200A1.
- Research Square Print. November 29th, 2022.
- Research Square Print. November 29th, 2022.
- Oxid Med Cell Longev. 2022 May 24:2022:4930643. [Abstract]
- J Oncol. 2022 Mar 10:2022:9055954. [Abstract]
- Seoul National University. Molecular medicine and Biopharmaceutical sciences. 2021 Dec.
- Mater Sci Eng C Mater Biol Appl. 2021 Apr:123:111956. [Abstract]
- Research Square Preprint. 2021 Jan.
- Nanotheranostics. 2021 Jan 1;5(2):143-154. [Abstract]
- Nanotheranostics. 2021 Jan 1;5(2):143-154. [Abstract]
- Oncotarget. 2017 Dec 2;8(68):112313-112329. [Abstract]
- Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
Description
IC50 & Target
[1]|
CYP3A |
In Vitro
Docetaxel (2 nM; 24 h) hydrate induces subdiploidy in MDA-MB-231, a process that requires passage through mitosis and is attenuated by MG132 (HY-13259), whereas 100 nM causes mitotic arrest[5].
Docetaxel (4-100 nM; 24 h) hydrate induces abnormal mitosis with small mononuclei in MCF7 cells at 4 nM, whereas 100 nM induces multinucleated cells[5].
Docetaxel hydrate upregulates TNFRSF6/FAS in MCF7 and MDA-MB-231 cells in a concentration-independent manner; at 100 nM, it increases phosphorylation of p53, Bax, and Bcl-2, whereas 4 nM produces higher p21 in MCF7; the DNA damage marker phosphorylated H2AX is notably induced in MDA-MB-231[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Docetaxel (15-150 mg/kg; single bolus) hydrate in Sprague-Dawley rats, intraperitoneal administration compared with intravenous administration significantly increases peritoneal fluid drug exposure, reduces systemic plasma exposure, and alters drug accumulation levels in multiple peritoneal organs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Nephrotoxicity Study
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Flow cytometric DNA-content cell-cycle staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- Apoptosis Solutions
- Protocol for Cell Cycle
- Hepatotoxicity Study
- Subcutaneous Cell-Line-Derived Xenograft
Chemical Information
-
CAS No. 700367-34-6
-
Molecular Weight 825.89
-
Formula C43H55NO15
-
SMILES
O=C(OC(C)(C)C)N[C@@H](C1=CC=CC=C1)[C@H](C(O[C@@H]2C(C)=C([C@@H](O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@@]4([H])C[C@@H]3O)([H])[C@@H]5OC(C6=CC=CC=C6)=O)=O)C(C)(C)[C@@]5(O)C2)=O)O.O
-
Synonyms
RP-56976 hydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (183)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis. [Abstract]2026 Jun 17;11(1):238. PMID: 42303991 -
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]2022 Sep 12;7(1):317. PMID: 36097006 -
J Hematol Oncol
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis. [Abstract]2023 May 3;16(1):46. PMID: 37138326
Docetaxel hydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2023 May 3;16(1):46. [Abstract]
Under docetaxel treatment (0.5 nM, 1 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 48 hours), myeloid-like tumor hybrid cells were less sensitive than the RM1 cell line.
-
-
-
Mol Cancer
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy. [Abstract]2024 May 9;23(1):83. PMID: 38730475 -
Cancer Discov
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer. [Abstract]2026 Jun 22. PMID: 42329102 -
Adv Mater
Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]2025 Jul 4:e2505231. PMID: 40611758 -
Eur Urol
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. [Abstract]2021 Jun;79(6):722-733. PMID: 33153817 -
Cancer Res
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer. [Abstract]2025 Oct 9. PMID: 41066596 -
-
ACS Nano
Metabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy. [Abstract]2021 Apr 27;15(4):7179-7194. PMID: 33861924 -
-
Sci Transl Med
TSPAN8+ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. [Abstract]2024 Apr 3;16(741):eadj5705. PMID: 38569015
Docetaxel hydrate purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2024 Apr 3;16(741):eadj5705. [Abstract]
Growth inhibition by docetaxel (Doc) (0–10 μM) in TS− or TS+ CAFs isolated from patients with BC was observed. The survival rates of TSPAN8+ CAFs were enhanced compared with TSPAN8− CAFs when challenged with an equal dosage of docetaxel.
-
Biomark Res
2022 Jul 13;10(1):48. PMID: 35831872 -
Acta Pharm Sin B
Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy. [Abstract]2021 Apr;11(4):1069-1082. PMID: 33996418 -
J Clin Invest
Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity. [Abstract]2026 Mar 17:e200260. PMID: 41842971 -
J Exp Clin Cancer Res
LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network. [Abstract]2023 Aug 18;42(1):209. PMID: 37596700 -
Adv Sci (Weinh)
Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients. [Abstract]2026 Mar;13(13):e11408. PMID: 41486873 -
Adv Sci (Weinh)
Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer. [Abstract]2025 Jan;12(2):e2407662. PMID: 39563492
Docetaxel hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(2):e2407662. [Abstract]
Representative images and quantitative analysis of surviving clones after treatment of C4-2B and LNCaP cells with PBS or ECM1 protein (200 ng/mL) in the presence of docetaxel (10 μM) were shown.
Docetaxel hydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(2):e2407662. [Abstract]
Flow cytometry analysis showed representative images and quantification of apoptosis in C4-2B and LNCaP cells in the presence of docetaxel (10 μM). Docetaxel caused PCa cell apoptosis compared to that in the vehicle group.
-
Cell Rep Med
Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]2026 May 19;7(5):102757. PMID: 42013847 -
Cell Rep Med
A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma. [Abstract]2026 Feb 17;7(2):102622. PMID: 41707653 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
Biomaterials
Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer. [Abstract]2022 Oct:289:121783. PMID: 36084486 -
J Transl Int Med
Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma. [Abstract]2026 Mar 26;14(2):237-258. PMID: 42046805 -
J Control Release
Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. [Abstract]2024 Dec:376:829-841. PMID: 39491626 -
J Control Release
Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer. [Abstract]2023 Jan:353:490-506. PMID: 36460179 -
J Control Release
Management of lymph node metastasis via local chemotherapy can prevent distant metastasis and improve survival in mice. [Abstract]2021 Jan 10:329:847-857. PMID: 33065097 -
Cell Death Dis
PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]2026 Apr 3;17(1):449. PMID: 41932868 -
Cell Death Dis
2026 Mar 24;17(1):363. PMID: 41876450 -
Cell Death Dis
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]2025 Mar 12;16(1):170. PMID: 40075071 -
Cell Death Dis
Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs. [Abstract]2024 Aug 7;15(8):571. PMID: 39112478 -
Pharmacol Res
2024 Jun:204:107208. PMID: 38729587 -
Cancer Lett
Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. [Abstract]2025 Feb 1:610:217339. PMID: 39608442 -
Cancer Lett
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs. [Abstract]2023 Sep 1:571:216338. PMID: 37549770 -
J Immunother Cancer
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. [Abstract]2021 Jul;9(7):e001758. PMID: 34301812 -
Phytomedicine
Artemisitene induces apoptosis of breast cancer cells by targeting FDFT1 and inhibits the growth of breast cancer patient-derived organoids. [Abstract]2024 Dec:135:156155. PMID: 39461203 -
Phytomedicine
Sculponeatin A promotes the ETS1-SYVN1 interaction to induce SLC7A11/xCT-dependent ferroptosis in breast cancer. [Abstract]2023 Aug:117:154921. PMID: 37327642 -
Phytomedicine
Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle. [Abstract]2023 Jan:109:154584. PMID: 36610114 -
Phytomedicine
Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling. [Abstract]2022 May:99:153939. PMID: 35172257 -
Mater Today Bio
Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity. [Abstract]2026 Mar 31:38:103086. PMID: 42006712 -
ACS Sens
Cryopreservable Through-Hole Arrays for the High-Throughput Three-Dimensional Smartphone-Based Cell Colorimetric Assay. [Abstract]2023 Feb 24;8(2):543-554. PMID: 36705290 -
Genome Med
Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. [Abstract]2024 Jan 12;16(1):11. PMID: 38217005 -
-
-
J Colloid Interface Sci
Smart dual responsive nanocarriers with reactive oxygen species amplification assisted synergistic chemotherapy against prostate cancer. [Abstract]2022 May 2;622:789-803. PMID: 35544966 -
Proc Natl Acad Sci U S A
Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. [Abstract]2023 Apr 25;120(17):e2218522120. PMID: 37068243 -
Diabetes
FGF13-sensitive alteration of Parkin safeguards mitochondrial homeostasis in endothelium of diabetic nephropathy. [Abstract]2023 Jan 1;72(1):97-111. PMID: 36256844 -
Oncogene
HOMER3 drives oral squamous cell carcinoma progression through TRPV6 calcium influx and TUBB3 microtubule stabilization. [Abstract]2026 Jan;45(2):278-294. PMID: 41326663 -
Oncogene
Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation. [Abstract]2025 Nov;44(45):4405-4412. PMID: 41046255 -
Int J Mol Med
Paeoniflorigenone inhibits ovarian cancer metastasis through targeting the MUC1/Wnt/β‑catenin pathway. [Abstract]2024 Jul;54(1):60. PMID: 38785138 -
Arch Pharm Res
Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition. [Abstract]2024 Nov;47(10-11):829-853. PMID: 39482441 -
Biofabrication
2023 Jun 9;15(3). PMID: 37236173 -
Cell Mol Gastroenterol Hepatol
2021;11(3):683-696. PMID: 33075564 -
Free Radic Biol Med
Targeted delivery of nebivolol via lactoferrin-modified liposomes inhibits NEK7-mediated pyroptosis to ameliorate inflammatory bowel disease. [Abstract]2026 Aug 16:252:493-508. PMID: 42061481 -
-
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097 -
ACS Appl Mater Interfaces
Single-Cell Fluidic Force Spectroscopy Reveals Dynamic Mechanical Fingerprints of Malignancy in Breast Cancer. [Abstract]2024 Sep 25;16(38):50147-50159. PMID: 39105773 -
ACS Appl Mater Interfaces
Glutathione and Esterase Dual-Responsive Smart Nano-drug Delivery System Capable of Breaking the Redox Balance for Enhanced Tumor Therapy. [Abstract]2023 May 3;15(17):20697-20711. PMID: 37083309 -
Cell Rep
Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. [Abstract]2024 Jul 3;43(7):114431. PMID: 38968071 -
Br J Pharmacol
2024 Nov;181(21):4279-4293. PMID: 38982588 -
Cancer Cell Int
2024 Dec 27;24(1):433. PMID: 39731167 -
Cancer Cell Int
Activation of the PERK/eIF2α axis is a pivotal prerequisite of taxanes to cancer cell apoptosis and renders synergism to overcome paclitaxel resistance in breast cancer cells. [Abstract]2024 Jul 17;24(1):249. PMID: 39020371 -
Drug Deliv Transl Res
Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer. [Abstract]2021 Oct;11(5):2030-2051. PMID: 33215254 -
J Agric Food Chem
Eurochevalierines A - I, Sesquiterpene Alkaloid Hybrids with Anti-Triple Negative Breast Cancer Activity from Penicillium sp. HZ-5. [Abstract]2024 Jul 31;72(30):16801-16811. PMID: 39016690 -
Eur J Med Chem
Jatrophane diterpenoids from Euphorbia sororia as potent modulators against P-glycoprotein-based multidrug resistance. [Abstract]2018 Feb 25:146:157-170. PMID: 29407947 -
Cell Biosci
2023 Nov 25;13(1):215. PMID: 38007480 -
Biochem Pharmacol
Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. [Abstract]2020 May;175:113865. PMID: 32142727 -
Life Sci
A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]2026 Mar 15:389:124236. PMID: 41611204 -
Life Sci
N6-methyladenosine-modified circQKI inhibits prostate cancer docetaxel-sensitivity via miR-188-3p/Beclin-1 pathway. [Abstract]2025 Jul 1:372:123646. PMID: 40250752 -
Life Sci
Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment. [Abstract]2021 Jan 1:264:118674. PMID: 33129876 -
Life Sci
Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. [Abstract]2020 Sep 1:256:117983. PMID: 32565252 -
Breast Cancer Res
TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9. [Abstract]2024 Mar 19;26(1):48. PMID: 38504374 -
-
-
Int J Pharm
Surface-modified nanoparticles of docetaxel for chemotherapy of lung cancer: an intravenous to oral switch. [Abstract]2023 Apr 5:636:122846. PMID: 36921744 -
Commun Biol
A compatible gravity-driven organoid perfusion (GDOP) platform for drug screening with sensitivity and toxicity process evaluation. [Abstract]2026 Apr 2;9(1):718. PMID: 41922471 -
Cancer Immunol Immunother
Construction and application of a humanized mouse model for prostate cancer in immunotherapy. [Abstract]2025 Nov 18;74(12):377. PMID: 41251708 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Cancer Biol Ther
Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. [Abstract]2026 Dec 31;27(1):2676474. PMID: 42189063 -
Clin Epigenetics
Investigating the mechanisms by which low NAT1 expression in tumor cells contributes to chemo-resistance in colorectal cancer. [Abstract]2025 May 6;17(1):77. PMID: 40329330 -
Pharmaceuticals (Basel)
Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis. [Abstract]2024 Apr 29;17(5):569. PMID: 38794139 -
Int J Mol Sci
Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations. [Abstract]2022 Nov 19;23(22):14385. PMID: 36430869 -
Int J Mol Sci
Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells. [Abstract]2018 Dec 21;20(1):28. PMID: 30577600 -
Biol Direct
Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma. [Abstract]2024 Sep 11;19(1):79. PMID: 39256753 -
J Enzyme Inhib Med Chem
Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer. [Abstract]2026 Dec;41(1):2622725. PMID: 41665114 -
-
ACS Omega
Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]2024 Feb 28;9(10):11870-11882. PMID: 38496939 -
Chem Biol Interact
The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. [Abstract]2023 Mar 1:373:110372. PMID: 36736488 -
J Mol Med (Berl)
Tyrosine hydroxylase as a therapeutic target: insights from adrenergic nerve and TNBC cell interactions. [Abstract]2026 Mar 19;104(1):53. PMID: 41857421 -
Mol Med Rep
miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway. [Abstract]2020 Jul;22(1):67-76. PMID: 32377748 -
-
Sci Rep
2025 Jul 4;15(1):23847. PMID: 40615482 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Sci Rep
Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation. [Abstract]2024 Mar 27;14(1):7303. PMID: 38538642 -
Cancer Sci
NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. [Abstract]2024 Feb;115(2):412-426. PMID: 38115797 -
Transl Oncol
MiR-138-5p inhibits prostate cancer cell proliferation and chemoresistance by targeting APOBEC3B. [Abstract]2023 Sep:35:101723. PMID: 37364333 -
Sci Rep
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening. [Abstract]2023 Jun 3;13(1):9043. PMID: 37270558 -
Eur J Med Res
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]2025 Aug 4;30(1):704. PMID: 40760677 -
Cancers (Basel)
Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. [Abstract]2020 Jul 28;12(8):2092. PMID: 32731472 -
J Cell Mol Med
Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer. [Abstract]2025 Dec;29(23):e70972. PMID: 41328625 -
-
J Cell Mol Med
Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function. [Abstract]2022 Apr;26(8):2392-2403. PMID: 35224849 -
J Liposome Res
Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. [Abstract]2020 Jun;30(2):182-196. PMID: 31060404 -
Mol Oncol
Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]2026 Jun 5. PMID: 42246237 -
iScience
Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis. [Abstract]2025 Oct 30;28(12):113908. PMID: 41321627 -
iScience
ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. [Abstract]2025 Sep 9;28(10):113520. PMID: 41069850 -
Biochim Biophys Acta Mol Cell Res
Cancer-associated fibroblasts secreting IL-6 inhibit the cisplatin and docetaxel killing effect in lung squamous cell carcinoma. [Abstract]2025 Jul 31;1872(8):120029. PMID: 40752594 -
FEBS J
2024 Jul;291(14):3249-3266. PMID: 38712529 -
Pharm Res
Active Targeting of Colorectal Cancer Using Chemotherapy-Loaded Nanoparticles Functionalized with a Folate Receptor-α (FRα) Ligand, Pemetrexed. [Abstract]2025 Nov 18. PMID: 41254319 -
BJU Int
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. [Abstract]2025 Nov 3. PMID: 41178321 -
BMC Cancer
Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis. [Abstract]2025 Jul 1;25(1):1042. PMID: 40597047 -
Front Biosci (Landmark Ed)
Hypoxia-Induced VGF Promotes Cell Migration and Invasion in Prostate Cancer via the PI3K/Akt Axis. [Abstract]2025 Feb 20;30(2):25522. PMID: 40018933 -
J Biol Chem
Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. [Abstract]2021 Jan-Jun:296:100276. PMID: 33428943 -
PLoS Genet
Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment. [Abstract]2025 Mar 31;21(3):e1011652. PMID: 40163511 -
Int J Med Sci
Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. [Abstract]2026 Jan 1;23(1):161-176. PMID: 41399371 -
Pathol Res Pract
Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]2025 Sep:273:156138. PMID: 40694986 -
Breast Cancer
Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer. [Abstract]2024 Dec 20:16:993-1004. PMID: 39720358 -
Materials
Antitumor Efficacy of Focused Ultrasound-MFL Nanoparticles Combination Therapy in Mouse Breast Cancer Xenografts. [Abstract]2020 Mar 2;13(5):1099. PMID: 32121631 -
Micromachines
Integrated Experimental-Computational Framework for Drug Transport Quantification in 3D Microtissues™. [Abstract]2026 Mar 9;17(3):332. PMID: 41900218 -
Mol Carcinog
ZNF480 Accelerates Chemotherapy Resistance in Breast Cancer by Competing With TRIM28 and Stabilizing LSD1 to Upregulate the AKT-GSK3β-Snail Pathway. [Abstract]2025 Jan;64(1):192-208. PMID: 39503216 -
Arch Biochem Biophys
KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation. [Abstract]2023 Mar 15:737:109551. PMID: 36822388
Docetaxel hydrate purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2023 Mar 15:737:109551. [Abstract]
Docetaxel (30 nM) exhibits anti-tumor activity in parental (DU145 and PC-3) and docetaxel-resistant (DU145/DTX50 and PC-3/DTX30) cell lines by down-regulating KIF14 expression.
-
Reprod Toxicol
Protective effects of rutin against docetaxel-induced testicular damage in rats: Effects on antioxidant defence, apoptosis and autophagy. [Abstract]2026 Jan:139:109110. PMID: 41248718 -
Transl Lung Cancer Res
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]2024 Oct 31;13(10):2698-2712. PMID: 39507032 -
Front Oncol
2019 Dec 19:9:1398. PMID: 31921655 -
Chem Biol Drug Des
Polyphyllin VII Enhances the Sensitivity of Prostate Cancer Cells to Docetaxel by Promoting Mitochondrial Dysfunction and Inducing Ferroptosis. [Abstract]2025 Feb;105(2):e70053. PMID: 39871642 -
Biochem Biophys Rep
Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells. [Abstract]2024 Jan 14:37:101639. PMID: 38288281 -
Breast Cancer Res Treat
2023 Jul;200(2):193-201. PMID: 37204665 -
J Cancer Res Clin Oncol
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs. [Abstract]2022 Dec;148(12):3511-3520. PMID: 35962287 -
-
-
J Microencapsul
Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-loaded nanostructured lipid carriers for improved antitumor activity against non-small cell lung carcinoma. [Abstract]2020 Dec;37(8):543-556. PMID: 32924677 -
J Microencapsul
Docetaxel-loaded PAMAM-based poly (γ-benzyl-l-glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles in human breast cancer and human cervical cancer therapy. [Abstract]2019 Sep;36(6):552-565. PMID: 31403342 -
Pharm Dev Technol
Dual-modified PCL-PEG nanoparticles for improved targeting and therapeutic efficacy of docetaxel against colorectal cancer. [Abstract]2021 Oct;26(8):910-921. PMID: 34280065 -
-
PLoS One
RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway. [Abstract]2026 Jan 21;21(1):e0341445. PMID: 41563982 -
Discov Oncol
Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel. [Abstract]2023 May 27;14(1):82. PMID: 37243787 -
Clin Transl Oncol
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]2022 Nov;24(11):2231-2240. PMID: 35852680 -
-
Biochem Biophys Res Commun
Vindoline, a vinca alkaloid derived from Catharanthus roseus, targets ABCB1 to overcome docetaxel resistance in prostate cancer. [Abstract]2026 Jun 18:818:153767. PMID: 42000630 -
Oncol Lett
PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/p-eIF4B/XIAP signaling pathway in prostate cancer. [Abstract]2022 Mar;23(3):101. PMID: 35154432 -
Anticancer Drugs
Exosomal circRNA Scm-like with four malignant brain tumor domains 2 (circ-SFMBT2) enhances the docetaxel resistance of prostate cancer via the microRNA-136-5p/tribbles homolog 1 pathway. [Abstract]2022 Oct 1;33(9):871-882. PMID: 36136987 -
Eur J Histochem
Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2 axis. [Abstract]2022 Oct 25;66(4). PMID: 36281649 -
Biomed Chromatogr
Investigation of the apoptosis-inducing effect of docetaxel by comprehensive LC-MS-based metabolomics and network pharmacology approaches. [Abstract]2022 Sep;36(9):e5417. PMID: 35633112 -
Mol Biol Res Commun
Combinatorial effects of telmisartan and docetaxel on cell viability and metastatic gene expression in human prostate and breast cancer cells. [Abstract]2022 Mar;11(1):11-20. PMID: 35463822 -
-
-
-
-
-
-
bioRxiv
Loss of PIK3CA allows in vitro growth but not in vivo progression of KRAS mutant lung adenocarcinoma in a syngeneic orthotopic implantation model. [Abstract]2026 Feb 4:2026.02.02.701385. PMID: 41676515 -
-
-
-
-
-
-
Res Sq
Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. [Abstract]2025 May 16:rs.3.rs-6590535. PMID: 40470249 -
-
-
bioRxiv
Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cells. [Abstract]2025 Jan 24:2025.01.22.632572. PMID: 39896568 -
-
-
bioRxiv
Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles. [Abstract]2023 Nov 1:2023.10.29.564598. PMID: 37961545 -
Biomed Pharmacother
Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy. [Abstract]2023 Sep:165:115023. PMID: 37329708 -
-
Biomed Pharmacother
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]2023 Jul:163:114751. PMID: 37105073 -
-
-
-
-
Oxid Med Cell Longev
2022 May 24:2022:4930643. PMID: 39282153 -
J Oncol
Solamargine Inhibits Prostate Cancer Cell Growth and Enhances the Therapeutic Efficacy of Docetaxel via Akt Signaling. [Abstract]2022 Mar 10:2022:9055954. PMID: 35310915 -
-
Mater Sci Eng C Mater Biol Appl
Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy. [Abstract]2021 Apr:123:111956. PMID: 33812584 -
-
Nanotheranostics
Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo. [Abstract]2021 Jan 1;5(2):143-154. PMID: 33457193 -
Nanotheranostics
Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo. [Abstract]2021 Jan 1;5(2):143-154. PMID: 33457193 -
Oncotarget
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]2017 Dec 2;8(68):112313-112329. PMID: 29348827 -
Oncotarget
Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. [Abstract]2016 May 17;7(20):28891-902. PMID: 27049720
Docetaxel hydrate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]
Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with XRP6258 (Cab). Graphs represent the densimetric semi-quantification of western blot images.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Docetaxel hydrate Related Classifications
HY-B0011B Related Classifications
Powered by Bioz